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1.  ABSTRACT 
Intraoperative use of IndoCyaninE Green fluorescence imaging to prevent anastomotic 
leakage in colorectal surgery: systematic review, meta-analysis and study protocol for 
the ICEberG trial 
Aim: ICG fluorescence imaging has been increasingly considered as a potential tool to assess 
anastomosis perfusion. This study aims to validate its efficacy in reducing anastomotic 
leakage (AL) rate in colorectal surgery. 
Method: A systematic review and a meta-analysis of studies comparing fluorescence imaging 
with standard care were conducted. Furthermore, a prospective randomised controlled trial 
(RCT) was proposed. 
Results: 1302 patients from 5 studies were included. Fluorescence imaging significantly 
reduced AL risk in cancer surgery (OR:0.34; CI:0.16-0.74; P=0.006). Low AL rates were 
shown in rectal surgery (ICG:1.1% vs non-ICG:6.1%; P=0.02). There was no significant AL 
rate decrease when procedures for benign and malignant indication were combined. To date, 
there are no published RCTs, though 3 ongoing trials were identified.  
Conclusions: Fluorescence imaging seems to reduce AL rate following colorectal surgery for 
cancer. However, large well-design RCTs are needed to provide evidence for its routine use. 
The proposed ICEberG trial would address this need.  
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Ús intraoperatori d’imatges per fluorescència amb verd d’indocianina per la prevenció 
de la fuita anastomòtica en cirurgia colorectal: revisió sistemàtica, meta-anàlisi i 
protocol per l’assaig clínic ICEberG 
Objectiu: L’ús d’imatges per fluorescència amb verd d’indocianina s’està considerant cada 
cop més com una potencial eina per l’avaluació de la perfusió de l’anastomosi. L’objectiu 
d’aquest estudi és validar la seva eficàcia en la reducció de la taxa de fuita anastomòtica en la 
cirurgia colorectal.  
Mètodes: S’ha realitzat una revisió sistemàtica i un meta-anàlisi dels estudis que comparaven 
l’ús d’imatges per fluorescència amb la pràctica habitual. A més, s’ha proposat un assaig 
controlat aleatori (ACA) prospectiu.  
Resultats: 1302 pacients de 5 estudis van ser inclosos a l’anàlisi. L’ús d’imatges per 
fluorescència va reduir significativament el risc de fuita en cirurgia per càncer (OR:0.34; 
CI:0.16-0.74; P=0.006). Es va veure una baixa taxa de fuita anastomòtica en cirurgia de recte 
(ICG:1.1% vs no-ICG:6.1%; P=0.02). No es va trobar un descens significatiu en la taxa de 
fuita anastomòtica quan es van combinar procediments amb indicació benigna i maligna. 
Actualment no existeixen ACA publicats, tot i que s’han identificat 3 assaigs en curs.  
Conclusions: L’ús d’imatges per fluorescència sembla reduir la taxa de fuita anastomòtica 
després de cirurgia colorectal per càncer. No obstant, es necessiten grans ACA que 
proporcionin evidència en l’ús d’aquesta tècnica a la pràctica habitual. El proposat ACA 
ICEberG abordaria aquesta necessitat.  
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2. BACKGROUND 
Anastomotic leakage (AL) represents one of the most feared complications following 
colorectal surgery; it has been associated with increased postoperative morbidity and 
mortality rates. (1,2) Due to the lack of a standardized definition for AL, there is still 
variability in studies reporting this condition. (3) In 2010, an attempt to define AL in anterior 
rectal resections was made by the International Study Group of Rectal Cancer. The definition 
proposed for AL was “a defect of the intestinal wall at the anastomotic site leading to a 
communication between the intraluminal and extraluminal compartments” and they 
recommended considering a pelvic abscess in the proximity of the anastomosis as AL. In 
addition, different AL grades were established according to their clinical management: Grade 
A when no change in patients’ management was required; Grade B if active therapeutic 
intervention was needed without surgical intervention; Grade C when re-
laparotomy/laparoscopy was performed. (4) Kulu et al. (5) proved this AL definition and 
severity grading to be a simple, easily applicable, and valid classification. 
AL rate in colorectal surgery vary from 1% to 19% depending on the anatomic location of the 
anastomosis: ileocolic (1% to 8%); colocolic (2% to 3%); ileorectal (3% to 7%); colorectal or 
coloanal (5% to 19%). (3,6,7) In the Rectal Cancer Project of the Spanish Society of 
Surgeons, the rate of AL for rectal cancer surgery was 10%. (8) The reduction of AL rates by 
improving its prevention, diagnosis and management, continues being a challenge nowadays. 
Finding new techniques to reduce AL has been highlighted as a research priority by the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI). (9)  
Multiple conditions have been associated with a greater risk of AL: male sex, age, 
comorbidities, high American Society of Anaesthesiologists (ASA) score, malnutrition, 
obesity, smoking, immunosuppression, alcohol abuse, preoperative chemotherapy and 
radiotherapy, advance tumour stage, diverticulitis, low anastomoses, prolonged operative 
R. Blanco Colino           Intraoperative use of ICG fluorescence imaging to prevent AL in colorectal surgery 
5 
 
time, inadequate anastomotic blood supply, blood loss or perioperative blood transfusion and 
intraoperative septic conditions appearance. (3,10–12) Adequate perfusion of the anastomosis 
is essential for an optimal healing and AL prevention. (13–15) Consequently, bowel ischemia 
detected intraoperatively may reduce the risk of AL.  
Different intraoperative techniques have been proposed to assess anastomotic integrity and 
bowel viability in colorectal surgery. Traditionally, usual anastomotic assessment includes 
direct visualisation of the anastomosis, integrity of doughnuts assessment and the air leak test. 
Subjective signs indicating optimal anastomosis perfusion are evaluated including serosal - 
mucosal colour and/or bleeding at the cut edge of the bowel and/or palpable pulsations of 
mesenteric arteries. (12,16) However, surgeons’ predictive accuracy of AL risk has been 
shown to be low and underestimated in the study of Karliczek et al. (17) They suggest the 
need of a reliable predictive test that could be used intraoperatively. Although there is no 
consensus on the use of air leak test in colorectal anastomosis, it is a widespread and well-
stablished technique. It consists in filling the pelvis with warm saline solution covering the 
anastomosis, then air is insufflated on the rectum to identify any possible leak. (3) This is a 
mechanical test, without any insight in the physiology of AL.  
Other experimental techniques assessing blood supply and/or integrity of anastomosis have 
been described. Some of them are intraoperative endoscopy, pulse oximetry, Doppler 
ultrasound and Doppler flowmetry, intramucosal pH measurement, visible light oxygen 
spectroscopy and near infrared oxygen spectroscopy. None of the mentioned techniques are 
routinely used, mainly because of its complexity and its high variability of the measurements. 
(16,18,19)  
Fluorescence imaging with indocyanine green (ICG) has been increasingly considered as a 
potential intraoperative tool that could be used in routine practice to ensure adequate 
perfusion at the time of anastomosis formation. It allows surgeons to visualize bowel 
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microperfusion at a real-time being a fast technique which is easy to perform. Recent 
literature shows the potential benefit of fluorescence imaging with ICG in lowering AL rates 
by changing the surgical plan. (20–26) Although it has been proven to be a safe and feasible 
tool in colorectal surgery, (27–29) further research is needed to validate its efficacy in 
reducing AL rate. (1)  
ICG is a sterile, water-soluble, trycarbocyanine compound dye that absorbs near-infrared light 
in the region of 800-810 nm and emits it at 830 nm. ICG is administered by intravenous 
injection (1.25 – 3.75 mg, depending on the patient weight) and it is rapidly bounded to 
albumin with minimal leakage into the interstitium. ICG is removed from the blood by the 
liver with a half-life of 3-5 minutes and then it is excreted via the bile within 10-15 minutes 
with no known metabolites. (30,31) Since 1956, when ICG was approved for clinical and 
research use in humans by the Food and Drug Administration (FDA), it has been used in 
different areas including plastic surgery, neurosurgery, ophthalmology, hepatobiliary and 
transplant surgery. The ICG applications with greater interest in colorectal surgery are 
anastomosis perfusion assessment and lymphatic road-mapping. Fluorescence imaging for 
bowel perfusion assessment can be used immediately before and/or after anastomosis 
formation once tissues are in their anatomic positions. (32) ICG clinical use has been proven 
to be very safety and rare cases of anaphylaxis have been described. (33) However, it should 
be used with caution in patients with iodine allergy (allergic reaction 1/300000). Moreover, 
manufacturers recommend a maximum daily dose of less than 2 mg/kg. (30,32,34) 
There are different platforms available to perform fluorescence imaging with ICG. SPY 
EliteTM system from Novadaq® was designed to be used in open cases and it provides a 
numeric assessment of perfusion. In laparoscopic surgery, the PINPOINTTM from Novadaq® 
(Canada), IC-View® from Pulsion Medical Systems (Germany) and the D-Light from Storz® 
(Germany) can be used. For robotic surgery, FIREFLYTM system integrated in surgical 
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robotic platform da Vinci SITM (USA) is available. In white light mode, these systems provide 
a standard laparoscopic view and it can be readily switched to near-infrared (NIR) mode, in 
which ICG fluorescence is visualised. Also, PINPOINTTM has a dual display mode allowing 
to superimpose green ICG fluorescence with white-light image. (30,35) These commercial 
available systems lack to provide a quantification of tissue perfusion. (1) 
 
Figure 1: Bowel perfusion assessment with ICG fluorescence using FIREFLY system during a robotic sigmoid 
colectomy (“A” and “C” show bowel/rectum in standard white light mode; “B” and “D” show bowel/rectum 
perfusion assessed with fluorescence mode after ICG administration). “A” and “B” correspond to bowel 
perfusion assessment while planning transection point. In “B”, well perfused bowel is indicated by white arrows 
and non-perfused bowel is indicated by black arrow. “C” and “D” pictures correspond to rectal stump 
assessment (white arrow). 
 
3. HYPOTHESIS AND OBJECTIVES 
We hypothesized that anastomosis perfusion assessment using ICG fluorescence imaging may 
be associated with a low leak rate in those patients undergoing colorectal surgery. 
This study aims to validate ICG fluorescence imaging efficacy in reducing the rate of AL in 
colorectal resections comparing with standard surgical care. As secondary aim, changes in 
surgical plan when anastomosis formation will be also considered.  
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4. SYSTEMATIC REVIEW AND META-ANALYSIS 
4.1. Material and methods 
A systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement. (36)  
Eligibility criteria 
Studies that compared intraoperative use of ICG fluorescence imaging with standard care for 
the assessment of anastomosis perfusion or viability, were eligible for inclusion. Patients of 
any age undergoing colon or rectal resection with anastomosis were included, regardless of 
operative approach, urgency of surgery and surgical indication.  The primary outcome 
measure was the AL rate with at least 30 days follow-up. Randomized Controlled Trials 
(RCTs), cohort studies, case-control studies and quasi-randomised studies were searched. 
Case reports were excluded. Studies using ICG fluorescence for other purposes different from 
perfusion assessment were excluded, as well as those studies based on animal models.  
Search strategy 
An electronic search was carried out using PubMed, Scopus, Web of Science, Google Scholar 
databases and the Cochrane Library. The reference list of identified systematic reviews and 
review articles were hand-searched for additional references. Furthermore, the register 
ClinicalTrials.gov was searched to identify ongoing trials. A combination of medical subject 
heading (MeSH) terms and keywords were searched: “indocyanine green”, “ICG”, “coloring 
agents”, “fluorescence”, “fluorescein angiography”, “fluorescent dyes”, “anastomotic leak”, 
“anastomotic leakage”, “anastomotic perfusion”, “anastomosis, surgical”, “bowel perfusion”, 
“blood supply”, “perfusion assessment”, “colorectal surgery”, “colon surgery”, “rectal 
surgery” “colorectal resection”, “bowel resection” using the Boolean operator “OR” for each 
concept. Each concept was combined with “AND”. The complete search strategy is shown in 
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the Appendix. No search limits were applied and all languages were included. The latest date 
of this search was 24th January 2017.  
Study selection and data extraction 
Studies were screened by title and abstract; then full-text was obtained for those studies 
identified as potentially eligible.  
From each study, data were extracted on: study characteristics and year of publication, patient 
inclusion period, sample size, surgical indication, surgical management (operative approach, 
procedure and whether a change in surgical plan was made), fluorescence imaging system 
used and anastomotic leakage rate. Authors were contacted to provide additional information 
that was not available in the original studies; two authors could not be contacted or were not 
able to provide the requested data. (37,38) 
Risk of bias assessment 
The quality of the included studies was evaluated using the ROBINS-I risk of bias assessment 
tool for non-randomized studies of interventions. (39) Seven domains were covered including 
confounding and selection of participants into the study, classification of interventions, 
deviations from intended interventions, missing data, measurement of outcomes, and selection 
of the reported result. 
Statistical analysis 
Analyses were performed using Review Manager (RevMan) Version 5.3 (Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The odds ratios (OR) were 
calculated from the original data and were assessed as the summary statistic. Values were 
reported with 95% confidence intervals (CI). As there was a substantial level of heterogeneity 
expected across the included studies, Mantel-Haenszel (M-H) method and random-effects 
models were employed for quantitative statistical analysis of dichotomous variables. 
Statistical heterogeneity was assessed using I2 test and by visual inspection of forest plots.  
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4.2. Results 
Study selection 
Results of literature search and selection process of eligible studies is presented on the 
PRISMA flow diagram (Figure 2). From the 518 studies identified by the search, full-text of 
72 studies was evaluated. Finally, 5 non-randomised studies were included in the analysis. 
(37,38,40–42) To date, there are no published RCTs. On ClinicalTrial.gov search, 6 ongoing 
trials were identified, 3 of them were randomized studies that have a control group. (43–45)  
 
Figure 2: PRISMA flow chart of study selection process 
Study characteristics 
Characteristics of the analysed studies are reported in Table 1. The five studies included a 
total of 1302 adult patients. The sample size in the studies varied from 38 to 436. Most studies 
included elective rectal surgery and the commonest indication was cancer. Follow-up ranged 
from 1 month to more than 6 months.   
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Risk of bias assessment 
The five included studies for analysis were non-randomised studies of interventions due to the 
lack of published RCTs. Most of the studies were retrospective and in some cases, they 
included small sample sizes. For these reasons, results should be taken with caution. Overall 
bias risk was evaluated with ROBINS-I tool. (39) All the studies were at moderate risk of bias 
when assessed as non-randomised studies. See the Appendix for supporting information. 
Outcome assessment 
A 
 
B 
 
C 
 
Figure 3: A) Forest plot showing odds ratio in AL following colorectal surgery in ICG group vs control group 
(non-ICG; standard care alone). B) Forest plot showing odds ratio in AL in patients undergoing any colorectal 
surgery for cancer indication in ICG group vs control. C) Forest plot showing odds ratio in AL in rectal cancer 
surgery in ICG group vs control. Mantel-Haenszel (M-H) method and random-effects model were used for meta-
analysis. OR shown with 95 per cent confidence intervals. 
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The meta-analysis included 555 patients in the ICG group and 747 patients in the control 
group. Both groups included patients who underwent colorectal surgery for benign and 
malignant indication. The overall AL rate was 5.4%. There was no significant difference in 
AL rate with or without the use of ICG fluorescence (OR 0.51; 95% CI 0.23-1.13; P= 0.10) 
(Figure 3A). The I2 value was 35%, which shows there was moderate heterogeneity.  
Data from 956 cancer patients was obtained from four studies. (37,40–42) AL risk was 
significantly reduced when using ICG fluorescence imaging in patients undergoing any 
colorectal surgery for cancer (OR: 0.34; CI: 0.16-0.74; P=0.006; I2 = 0%) (Figure 3B). Rectal 
cancer surgery was assessed in 554 patients in three studies (40–42). ICG perfusion 
assessment in rectal surgery resulted in an 81% reduction in the odds of AL presentation 
(OR:0.19; 95% CI 0.05-0.75; P= 0.02; I2 = 0%) (Figure 3C), showing a low AL rate in 
comparison with standard care (1.1% vs 6.1% respectively).  
A change in the planned anastomotic level was decided for 41 of the 555 patients in the ICG 
group (7.4%), due to hypoperfusion seen by ICG. Moreover, Kim et al. (41) reported 13 
patients over 123 in the ICG group (10.6%) and Kudszus et al. (37) reported 5 patients over 
201 (2.5%) in which further exploration with ICG after anastomosis formation helped to 
identify adequate perfusion despite clinical impression of malperfusion. None of those cases 
underwent additional resection o re-anastomosis.   
4.3. Discussion 
This systematic review and meta-analysis show that intraoperative use of ICG fluorescence 
imaging is a potential tool to reduce the AL risk following colorectal surgery for cancer. 
However, the inherent bias of the non-randomised studies included, should be taken into 
consideration when interpreting these findings. 
Morbidity, mortality and costs generated by this postoperative complication, may be reduced 
with a decrease in AL rate. ICG fluorescence system did not seem to affect cost-effectiveness. 
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The initial burden of a NIR unit are 70.000€ and then the cost for ICG dye is 13€ per patient. 
(41) In contrast, AL represents 1.6 to 5 million euros of the annual direct healthcare costs in 
the UK and over 22.000€ per patient in the USA. (3) AL also increases the mortality risk 
(from 1.9% without AL to 15.9% with AL) and, the length of stay (from 7 days without AL to 
23 days with AL). (11) In colorectal cancer surgery, AL has been associated with reduced 
long-term cancer specific survival and a greater risk for systemic and local recurrence. (46,47) 
However, this association remains unclear when referring to rectal surgery. (48)   
Several studies have assessed the use of ICG fluorescence in colorectal surgery, but most of 
them correspond to case series with small sample sizes. Fluorescence imaging has been 
described in surgical procedures for benign and malignant indication and different operative 
approaches (22–25,49) including robotic colorectal surgery, (20,26) transanal rectal surgery, 
(27) and minimally invasive surgery. (50)  
One of the limitations of this meta-analysis is the lack of randomisation in the studies 
included. In addition, four studies were retrospective (37,38,40,42) and results from ICG 
fluorescence group were compared with a control group from a different period of time. At 
present, there is no RCT published. Three ongoing RCTs were found on ClinicalTrial.gov 
register. AL rate is the primary outcome measure in the three studies, two of them with 30 
days follow-up (43,44) and one of them with 2 months follow-up. (45) One of the RCTs 
would include low anterior resections for rectal cancer, (45) other would evaluate ICG use 
during rectal or left colectomies (benign and malignant disease) (44) and the last one includes 
robotic colorectal surgery for cancer, IBD or diverticular disease indication. (43) 
Results of this study must be taken with caution due to the variability on AL definition, as 
well as differences in the length of follow-up, surgical technique and application of ICG on 
the experimental group. In all the included studies, ICG fluorescence was used before 
intestinal resection to plan transection level. In some cases, it was also used after the 
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anastomosis formation. (41,42) Moreover, the quantitative definition of an adequate or 
inadequate preanastomotic perfusion is not well defined, mainly because most of the actual 
imaging systems lack to quantify tissue perfusion. However, some experimental studies 
assessing fluorescence quantification in animal models have been published. (51) 
Additionally, Sherwinter et al. (27) used a fluorescence score in their study based on the 
sequence of fluorescence uptake and time of maximal excitation.  
ICG fluorescence seems to help in identifying the need for a change in the surgical plan, 
extending resection margins or requiring revision and re-anastomosis. A change in the 
planned anastomotic level was decided in 7.4% (41 over 555 patients in the ICG group). 
Usually, a change is decided if a bowel hypoperfusion is detected by fluorescence, even if it 
had seemed well-perfused by visual examination. In contrast, ICG fluorescence can also help 
confirm a competent perfusion in those cases with a clinical impression of malperfusion, and 
therefore not to extent the resection margins further.  
In the present meta-analysis, Kin et al. (38) was the only study that have reported a non-
reduction in AL rate when using intraoperative fluorescence. However, this study presents 
some limitations that could have influenced results. Only proximal bowel perfusion was 
assessed, and therefore rectal stump perfusion was not confirmed. In contrast with the other 
studies, which only included patients undergoing surgery for cancer indication, this study also 
included patients with inflammatory bowel disease and diverticular disease. 
Despite the limitation of the available studies, this systematic review and meta-analysis show 
that ICG fluorescence imaging is a promising tool that could change usual practice. It may 
reduce AL rate in patients undergoing colorectal resection for cancer indication. However, its 
use for benign indications is uncertain. There is a need of larger, well-designed RCTs to 
assess if AL rate can be reduced by incorporating ICG fluorescence imaging in routine 
colorectal surgery for benign or malignant indication.  
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5. STUDY PROTOCOL FOR THE ICEBERG TRIAL 
5.1. Rationale for a RCT on ICG use in colorectal surgery 
We propose a randomised controlled trial addressing the intraoperative use of ICG 
fluorescence imaging to reduce AL rate in patients undergoing colorectal surgery. 
The following issues justify the need of a RCT: 
1. There is no RCT published comparing ICG fluorescence imaging with standard care. 
2. There are 3 ongoing trials. PILLAR III, is a multicentre RCT that is including patients 
undergoing low anterior resection for rectal o rectosigmoid neoplasm. (45) The other two 
are single centre RCT; one is including patients undergoing robotic surgery (43) and the 
other includes laparoscopic rectal resections and left colectomies, (44) both studies 
include surgeries for benign and malignant indications. Therefore, there is no RCT 
addressing ICG fluorescence use in routine practice for any condition (benign and 
malignant) under laparoscopic or robotic approach, in total, right or left colectomies and 
rectal resection procedures. 
3. There is no current data assessing ICG dose, application, fluorescence diagnosis and 
management if a change in surgical plan is decided. 
5.2. Study design 
This is a prospective, multicentre, randomised controlled trial comparing intraoperative use of 
ICG fluorescence imaging with standard care alone in anastomosis formation.  
5.3. Outcome measures 
Primary outcome measure 
AL rate within a 60 days follow-up. AL will be defined and graded as Rahbari et al. proposed 
in their study. (4) Pelvic abscess in the proximity of the anastomosis will also be considered 
as AL. Stricture of the anastomosis will not be considered as AL.  
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C-reactive protein (CRP) as well as procalcitonin (PCT) have been suggested as useful 
screening markers for early prediction of AL on postoperative days 3-5. (52) Their levels will 
be used to determine if a CT scan for AL detection is necessary. 
Secondary outcome measure 
1. Number of cases in which a change in the surgical plan is decided. For example: 
extension of the resection margins; colon/rectum preservation; protective ileostomy 
(avoided or performed).  
2. Major postoperative complications defined by the Clavien-Dindo classification (53) grade 
III to V at 60 days of follow-up (see Appendix for more information).  
3. Length of stay, including from day 0 (day of surgery) to day of discharge. 
4. Fluorescence Reflection Score (on the experimental group) and Clinical Assessment 
Score (on both groups) for anastomosis evaluation. The Fluorescence Reflection Score 
corresponds to fluorescence reflection of the colon and rectum in the ICG fluorescence 
imaging arm. The Clinical Assessment Score is the evaluation of bowel appearance, the 
completeness of doughnuts and air leak test results in both arms. Following score has 
been adapted from the study of Sherwinter et al. (27): 
 
Score Clinical Assessment Score Fluorescence Reflection Score 
1 
Dusky appearance and/or positive air leak test 
and/or non-integrity of doughnuts 
No uptake 
2 
Pink appearance but no pulsatility of mesenteric 
vessels or no bleeding cut edges or alteration on 
bowel viability suspected 
Hypofluorescent or patchy 
fluorescence comparing with other 
segments 
3 
Pink appearance, pulsatility of mesenteric vessels, 
bleeding cut edges, no alteration on bowel 
viability. Complete anastomotic doughnuts. 
Negative air leak test. 
Isofluorescent to other segments  
Table 2: Clinical Assessment Score and Fluorescence Reflection Score for anastomosis evaluation. 
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5.4. Eligibility criteria 
Inclusion criteria 
 Adult patients (≥ 18 years) undergoing colorectal resection with a primary anastomosis 
(including right or left colectomy, total colectomy, sigmoid and rectal resection) will be 
included. Surgeries under laparoscopic or robotic approach for benign or malignant 
indication will be eligible for inclusion. 
Exclusion criteria 
 Patients with known allergy or history of adverse reaction to iodine or indocyanine green 
 Pregnant or breast-feeding patients 
 Patients undergoing emergency surgery 
 Patients undergoing colorectal resection without anastomosis 
 Patients undergoing palliative surgery for terminal illness 
 Not consenting patients 
 5.5. Site selection 
This study is proposed by the general surgery department, colorectal surgery unit at Hospital 
Universitari Vall d’Hebron. The ICEberG trial is a multicentre study and it will be performed 
in European colorectal units. Moreover, it is opened to other international centres interested in 
joining the trial. Sites will be eligible to participate based on fluorescence imaging system 
availability at their units, case volumes and surgical experience. 
5.6. Randomisation  
After obtaining written consent from the patients, they will be randomised by a web-based 
method on a 1:1 basis. Stratified randomisation will be performed by the planned surgical 
procedure: total colectomy, right colectomy, left colectomy, sigmoid resection, and rectal 
resection. 
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5.7. Blinding 
This trial is blinded to the patient. The trial design and the expected intervention on the 
experimental group do not enable to blind the surgeon performing the procedure.  
5.8. Interventions: experimental and control arm 
Standard care for AL detection will be performed in both arms and it will include:  
 Visual examination of both segments (before and after anastomosis) 
 Integrity of doughnuts assessment if applicable 
 Air leak test (after anastomosis) 
Intervention arm 
The intervention group consists on using ICG fluorescence imaging intraoperatively. 
Preoperative bowel preparation, as well as planned surgical procedure will be performed 
according to surgeon’s standard practice until time of transection point. A bolus of 0.1 – 0.3 
mg/kg of indocyanine green will be injected intravenously by the anaesthetist. If laparoscopic 
approach, PINPOINTTM system will be used. If robotic approach, then FIREFLYTM  will be 
the system used.  
Prior to fluorescence assessment, surgeon will visually examine anastomosis segments as it 
would be done in standard care and will assign a score following the “Clinical Assessment 
Score” presented on Table 2. Then, fluorescence of both segments of the anastomosis will be 
assessed and a score will be assigned by the surgeon according to the “Fluorescence 
Reflection Score” on Table 2 (1 no uptake to 3 maximal uptake). Once the anastomosis is 
done, “Clinical Assessment Score” and “Fluorescence Reflection Score” will be used again to 
assign a score after anastomosis performance. If a change on the surgical planned is decided, 
this will be noted on case report form. 
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Control arm – No intervention 
In the control group, only standard care will be performed. Therefore, both segments will be 
visually examined using the “Clinical Assessment Score” before and after anastomosis 
formation. If a change on the surgical planned is decided, this will be noted on case report 
form. 
5.9. Recruitment and trial timeline 
Patients undergoing colorectal surgery will be screened for eligibility. If the patient meets 
inclusion criteria and does not meet exclusion criteria, the surgeon will explain trial details to 
the patient. An information sheet about ICEberG trial will be available for patients. If the 
patient accepts and signs the informed consent, it can be randomised into one of the two 
branches. Intervention or non-intervention will take place during the surgical procedure.  
 
Figure 4: Trial flow chart 
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In order to detect AL postoperatively, all patients’ CRP levels will be evaluated on the 3rd 
postoperative day. If CRP is over 140 mg/L, then 4th postoperative day CRP and PCT will be 
evaluated. If at 4th day CRP is over 125 and PCT is over 0.4 ng/mL, then a CT scan with 
intravenous contrast will be ordered, adding rectal contrast if a rectum anastomosis was 
performed. 
Requirement of radiological or surgical management of an AL will be recorded, as well as 
major postoperative complications including death. Patients will be follow-up for at least two 
months.  
The end of the study is the date of the last follow-up for the last patient included in the study.  
5.10. Data management 
Data collection will include preoperative, intraoperative and postoperative details. Data will 
be collected on predesigned paper forms (see Appendix – case report form) and then, it will be 
entered into an electronic database system. 
5.11. Statistical methods  
Sample size 
In previously cohort studies in Europe, AL rate has ranged among 6% to 8% in colonic 
resections and among 10% to 12% for rectal resections. (7,8,54) 
Assuming an average of AL following colorectal surgery of a 9% in the control group and a 
3% in the experimental group based on published studies, accepting an alpha risk of 0.05 and 
a beta risk of 0.2, a total of 512 patients (256 patients each arm) are the minimum required for 
the study if a 10% of drop-out rate is assumed. The ARCSINUS approximation has been used. 
Statistical analysis 
Data analysis will be performed using R Foundation for Statistical Computing software (R 
version 3.3.1). For baseline characteristics, descriptive statistics will be used. Chi squared test 
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or Fisher’s Exact test will be used for categorical variables, including AL rate. For continuous 
outcomes, Student’s t test will be applied for normal distribution and Mann-Whitney U test 
for data that is not normally distributed. Univariate exploratory analysis and multiple logistic 
regression will be used to test risk factors associated with AL (see Appendix – case report 
form). P < 0.05 will be used as level of significance. 
5.12. Ethical considerations and trial registration 
The trial will be performed following the principles of the Declaration of Helsinki and Good 
Clinical Practice. (55) Before the start of the trial, protocol, information sheet and informed 
consent documents will be approved by the Ethical Committee at each participating centre. 
Recruitment will not start in any individual centre until local approval is obtained.  
Only patients who accept and sign the informed consent will be included. Participation in the 
study is voluntary and patients can withdraw consent at any time.  
The trial will be registered at the www.clinicaltrials.gov website.  
6. CONCLUSIONS 
Anastomotic leakage is still a common postoperative complication, which has been associated 
with greater morbidity and mortality rates. The findings of the systematic review and meta-
analysis performed, suggest that ICG fluorescence imaging is a promising tool to prevent AL 
in patients undergoing colorectal anastomosis. In order to stablish fluorescence imaging as 
part of routine colorectal surgery, randomised controlled trials are needed to provide evidence 
in its use. Therefore, ICEberG trial has been proposed in this work addressing this necessity. 
Finally, European and international collaboration among surgeons is essential to run powered 
studies which allow to address this issue together and, consequently, to get better outcomes 
for our patients. 
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1. ABBREVIATURES  
AL – Anastomotic leakage 
ICG – Indocyanine Green 
RCTs – Randomised Controlled Trials 
NIR – Near Infrared  
FA – Fluorescence Angiography 
ASA – American Society of Anaesthesiologists 
ACPGBI – Association of Coloproctology of Great Britain and Ireland  
FDA – Food and Drug Administration 
OR – Odds Ratio  
CI –  Confidence Intervals 
M-H – Mantel-Haenszel 
IBD – Inflammatory bowel disease 
LAR – Low anterior resection 
TME – Total mesorectal excision 
CT – Computerized tomography 
CRP – C-reactive protein 
PCT – Procalcitonin 
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2. SEARCH STRATEGIES 
Search strategy, PubMed: 
 (("indocyanine green"[MeSH Terms] OR ("indocyanine"[All Fields] AND "green"[All 
Fields]) OR "indocyanine green"[All Fields]) OR ICG[All Fields] OR ("colouring agents"[All 
Fields] OR "coloring agents"[Pharmacological Action] OR "coloring agents"[MeSH Terms] 
OR ("coloring"[All Fields] AND "agents"[All Fields]) OR "coloring agents"[All Fields]) OR 
("fluorescence"[MeSH Terms] OR "fluorescence"[All Fields]) OR ("fluorescein 
angiography"[MeSH Terms] OR ("fluorescein"[All Fields] AND "angiography"[All Fields]) 
OR "fluorescein angiography"[All Fields]) OR ("fluorescent dyes"[Pharmacological Action] 
OR "fluorescent dyes"[MeSH Terms] OR ("fluorescent"[All Fields] AND "dyes"[All Fields]) 
OR "fluorescent dyes"[All Fields])) AND (("anastomotic leak"[MeSH Terms] OR 
("anastomotic"[All Fields] AND "leak"[All Fields]) OR "anastomotic leak"[All Fields]) OR 
"anastomotic leakage"[All Fields] OR "anastomotic perfusion"[All Fields] OR ("anastomosis, 
surgical"[MeSH Terms] OR ("anastomosis"[All Fields] AND "surgical"[All Fields]) OR 
"surgical anastomosis"[All Fields] OR ("anastomosis"[All Fields] AND "surgical"[All Fields]) 
OR "anastomosis, surgical"[All Fields]) OR "bowel perfusion"[All Fields] OR ("blood 
supply"[Subheading] OR ("blood"[All Fields] AND "supply"[All Fields]) OR "blood 
supply"[All Fields]) OR "perfusion assessment"[All Fields]) AND (("colorectal 
surgery"[MeSH Terms] OR ("colorectal"[All Fields] AND "surgery"[All Fields]) OR 
"colorectal surgery"[All Fields]) OR "colon surgery"[All Fields] OR "rectal surgery"[All 
Fields] OR "colorectal resection"[All Fields] OR "bowel resection"[All Fields]) 
Search strategy, Scopus: 
( ALL ( ( "indocyanine green"  OR  icg  OR  "coloring agents"  OR  fluorescence  OR  
"fluorescein angiography"  OR  "fluorescent dyes" ) )  AND  ALL ( ( "anastomotic leak"  OR  
"anastomotic leakage"  OR  "anastomotic perfusion"  OR  "anastomosis,surgical"  OR  "bowel 
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perfusion"  OR  "blood supply"  OR  "perfusion assessment" ) )  AND  ALL ( ( "colorectal 
surgery"  OR  "colon surgery"  OR  "rectal surgery"  OR  "colorectal resection"  OR  "bowel 
resection" ) ) – All Fields 
Search strategy, Web of Science (Core Collection): 
TOPIC: (("indocyanine green" OR icg OR "coloring agents" OR fluorescence OR "fluorescein 
angiography" OR "fluorescent dyes")) AND TOPIC: (("anastomotic leak" OR "anastomotic 
leakage" OR "anastomotic perfusion" OR "anastomosis,surgical" OR "bowel perfusion" OR 
"blood supply" OR "perfusion assessment")) AND TOPIC: (("colorectal surgery" OR "colon 
surgery" OR "rectal surgery" OR "colorectal resection" OR "bowel resection")) 
Timespan: All years. 
Search strategy, Google Scholar: 
"indocyanine green" "anastomotic leakage" "colorectal surgery" 
Search strategy, Cochrane Library: 
("indocyanine green"  OR  icg  OR  "coloring agents"  OR  "fluorescence"  OR  "fluorescein 
angiography"  OR  "fluorescent dyes") AND ("anastomotic leak"  OR  "anastomotic leakage"  
OR  "anastomotic perfusion"  OR  "anastomosis,surgical"  OR  "bowel perfusion"  OR  "blood 
supply"  OR  "perfusion assessment") AND ("colorectal surgery"  OR  "colon surgery"  OR  
"rectal surgery"  OR  "colorectal resection"  OR  "bowel resection") – Search all text 
Search strategy, ClinicalTrials.gov: 
“indocyanine green” AND “colorectal” 
“indocyanine green” AND “rectal” 
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3. BIAS ASSESSMENT WITH ROBINS-I TOOL1 
 
ROBINS-I tool (Stage II): For each study 
 
ROBINS-I tool (Stage III): Overall risk of bias assessment 
 Kudszus et al. (37) – Overall MODERATE 
 Kin et al. (38) – Overall MODERATE  
 Jafari et al. (40) – Overall MODERATE 
 Kim et al. (41) – Overall MODERATE  
 Boni et al. (42) – Overall MODERATE 
 
                                                 
1 Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for 
assessing risk of bias in non-randomised studies of interventions. Br Med J [Internet]. 2016;355:i4919. Available 
from: http://www.bmj.com/lookup/doi/10.1136/bmj.i4919 
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Kudszus et al. (37) Moderate Low Low Low Low Moderate Low 
Kin et al. (38) Moderate Low Low Low Low Low Moderate  
Jafari et al. (40) Moderate Low Low Low Low Low Low 
Kim et al. (41) Moderate Low Low Low Low Moderate Low 
Boni et al. (42) Moderate Low Low Low Low Low Low 
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4. ICEBERG TRIAL – CASE REPORT FORM 
Patient code: 
Group assigned:   1  (ICG)    -     2  (Control) 
PREOPERATIVE DATA 
Age (years)*  
Gender  
BMI (kg/m2)  
ASA score* I                    II                      III                       IV                      
V                Unknown 
Past Medical History □ Ischaemic Heart Disease*  
□ Congestive Heart Failure 
□ Cerebrovascular Accident 
□ Diabetes  □ None  □ Diet/tablet  □ Insulin* 
□ Chronic Kidney Disease 
□ Chronic Respiratory Disease 
History of previous abdominal surgery Yes              No 
Current treatment  Anticoagulants      /    Corticosteroids* 
Neoadjuvant therapy (If cancer indication) Yes- Chemotherapy             Yes-Radiotherapy*    
Yes – Chemo + radiotherapy         No 
Smoking status 
For current and ex-smoker record pack year history: 
Current*                Ex-smoker                Never            
Unknown 
Last pre-operative serum albumin (g/dl)   
Last pre-operative serum haemoglobin (g/dl)  
INTRAOPERATIVE DATA 
Day of surgical intervention (DD/MM/YYYY)  
Preoperative bowel preparation Yes              No 
Surgical procedure  
Surgical indication* □ Malignant            □ Diverticular disease            
□ IBD        □ Other 
Surgical approach Laparoscopic         Robotic 
Type of anastomosis* □ Colo-colic 
□ Colo-rectal 
□ Ileo-colic 
□ Other:  _______________ 
Anastomosis - technical details* Hand-sewn       -     Stapled 
Length of operation (minutes)   
Clinical Assessment Score 
 (both segments) 
Before anastomosis Proximal: 1 -  2  -  3          Distal: 1 -  2  -  3    
After anastomosis Proximal: 1 -  2  -  3          Distal: 1 -  2  -  3    
Fluorescence Reflection 
Score (both segments) 
Before anastomosis Proximal: 1 -  2  -  3          Distal: 1 -  2  -  3    
After anastomosis Proximal: 1 -  2  -  3          Distal: 1 -  2  -  3    
Change in the surgical plan Yes              No 
If YES – indicate change: 
Performance of protective ileostomy Yes              No 
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POSTOPERATIVE DATA 
3rd postoperative day CRP level (mg/L)  
If applicable: 4th postop day CRP level (mg/L)  
If applicable: 4th postop day PCT level (ng/mL)  
CT scan findings None          AL          Pelvic abscess     Other 
Anastomotic leak (60 day follow-up) 
If AL - Please record postoperative day of diagnosis 
   No           Yes  Grade A / Grade B / Grade C 
Day:  
Length of stay (days)   
60-day Clavien-Dindo grade I             II             III                  IV                     V 
Readmission (if YES – indicate postoperative day) Yes              No 
Day: 
Reoperation (if YES – indicate postoperative day) Yes              No 
Day: 
Postoperative pain control with NSAIDS Yes              No 
TNM after surgery  (If cancer indication)  
(*) Variables associated with AL – for exploratory analysis on primary outcome measure 
Clavien Dindo Classification 
GRADE   DEFINITION 
I Any deviation from the normal postoperative course without the need for 
pharmacological (other than the “allowed therapeutic regimens”), surgical, 
endoscopic or radiological intervention. 
Allowed therapeutic regimens are: selected drugs (antiemetics, antipyretics, 
analgesics, diuretics and electrolyte replacement), physiotherapy and wound 
infections opened at the bedside but not treated with antibiotics. 
II Requiring pharmacological treatment with drugs beyond those allowed for 
grade I complications. Blood transfusions and total parenteral nutrition are also 
included. 
IIIa Requiring surgical, endoscopic or radiological intervention, not under general 
anaesthetic. 
IIIb Requiring surgical, endoscopic or radiological intervention, under general 
anaesthetic. 
IVa Life-threatening complications requiring critical care management – single 
organ dysfunction, or neurological complications including brain haemorrhage 
and ischemic stroke (excluding transient ischemic attack). 
IVb Life-threatening complications requiring critical care management – multi-
organ dysfunction. 
V Death of a patient 
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5. INFORMED CONSENT AND INFORMATION SHEET FOR THE 
ICEBERG TRIAL2 
Modelo de consentimento informado para el ensayo clínico ICEberG  
Título del estudio:  ICEberG trial: IndoCyaninE Green fluorescence imaging to 
prevent anastomotic leakage in colorectal surgery      
 
Yo _____________________________  (nombre y apellidos del participante) 
 
He leído la hoja de información que se me ha entregado. 
He podido hacer preguntas sobre el estudio. 
He hablado con: _____________________________   (nombre del investigador).  
 
Comprendo que mi participación es voluntaria. 
 
Comprendo que puedo retirarme del estudio:   
1.  Cuando quiera 
2.  Sin tener que dar explicaciones  
3. Sin que esto repercuta en mis cuidados médicos 
 
Presto libremente mi conformidad para participar en el estudio.  
Fecha y firma del participante          Fecha y firma del investigador  
 
 
 
                                                 
2 These documents are in Spanish as required by the Clinical Research Ethics Committee (CREC) of Hospital 
Universitari Vall d’Hebron.  
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Hoja de información al paciente para el ensayo clínico ICEberG 
Proyecto de investigación titulado ICEberG trial: IndoCyaninE Green fluorescence imaging to 
prevent anastomotic leakage in colorectal surgery  
Estimado paciente, 
Le solicitamos su participación en este proyecto de investigación cuyo objetivo principal es 
evaluar si el uso intraoperatorio de verde indocianina para la visualización directa de la 
vascularización colorrectal reduce la tasa de fuga de anastomosis. 
Beneficios: 
Es posible que de su participación en este estudio no obtenga un beneficio directo. Sin embargo, 
la evaluación de nuevas estrategias relacionadas con la prevención de la fuga anastomótica 
podría contribuir a una futura reducción de esta complicación postoperatoria.  
Procedimientos del estudio: 
En este estudio se pretenden comparar dos procedimientos. La asignación a uno de ellos vendrá 
determinada por el azar. Su médico no intervendrá en este proceso. Usted tendrá una 
probabilidad del 50% de recibir cada uno de los procedimientos contemplados en este estudio. 
El primer grupo contempla los procedimientos que se hacen usualmente en la práctica habitual 
durante la cirugía y en el segundo grupo, además de los procedimientos habituales se empleará 
el uso de verde de indocianina. Éste es un colorante que permite visualizar por fluorescencia la 
vascularización colorrectal y, por tanto, decidir cambios en el plan quirúrgico según precise 
para asegurar una anastomosis en zona viable con buena perfusión. 
Molestias y posibles riesgos: 
El verde de indocianina es un colorante seguro, de baja toxicidad y buena tolerancia. Se ha 
descrito algún caso de reacción anafiláctica en pacientes con alergia a la iodina o a contrastes 
iodados (1/300000). 
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Protección de datos personales: 
De acuerdo con la Ley 15/1999 de Protección de Datos de Carácter Personal, los datos 
personales que se obtengan serán los necesarios para cubrir los fines del estudio. En ninguno 
de los informes del estudio aparecerá su nombre, y su identidad no será revelada a persona 
alguna salvo para cumplir con los fines del estudio, y en el caso de urgencia médica o 
requerimiento legal. Cualquier información de carácter personal que pueda ser identificable 
será conservada por métodos informáticos en condiciones de seguridad. Cualquier información 
de carácter personal que pueda ser identificable será conservada por métodos informáticos en 
condiciones de seguridad. El acceso a dicha información quedará restringido al personal del 
hospital, designado al efecto o a otro personal autorizado que estará obligado a mantener la 
confidencialidad de la información.  
De acuerdo con la ley vigente, usted tiene derecho al acceso de sus datos personales; asimismo, 
y si está justificado, tiene derecho a su rectificación y cancelación. Si así lo desea, deberá 
solicitarlo al médico que le atiende en este estudio.  
De acuerdo con la legislación vigente, tiene derecho a ser informado de los datos relevantes 
para su salud que se obtengan en el curso del estudio. Esta información se le comunicará si lo 
desea; en el caso de que prefiera no ser informado, su decisión se respetará.  
Su participación en el estudio es totalmente voluntaria, y si decide no participar recibirá todos 
los cuidados médicos que necesite y la relación con el equipo médico que le atiende no se verá 
afectada. 
Agradecimiento: 
Le agradecemos el tiempo dedicado a la lectura de esta información. Por favor, tómese el tiempo 
necesario para leer toda la información y preguntar las dudas que le pudieran surgir. Si decide 
tomar parte en este estudio, deberá firmar el consentimiento informado conforme acepta su 
participación voluntaria en el ensayo clínico ICEberG. 
